Anavex Life Sciences Corp. (NASDAQ:AVXL - Get Free Report) shares crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $9.17 and traded as high as $10.93. Anavex Life Sciences shares last traded at $10.76, with a volume of 729,059 shares changing hands.
Analyst Upgrades and Downgrades
Several brokerages recently issued reports on AVXL. D. Boral Capital reissued a "buy" rating and set a $46.00 price objective on shares of Anavex Life Sciences in a research note on Monday, April 7th. HC Wainwright reissued a "buy" rating and set a $42.00 price objective on shares of Anavex Life Sciences in a research note on Monday, April 7th.
Check Out Our Latest Analysis on Anavex Life Sciences
Anavex Life Sciences Stock Up 3.9%
The company has a market cap of $954.44 million, a PE ratio of -20.33 and a beta of 0.72. The stock's 50 day simple moving average is $8.65 and its two-hundred day simple moving average is $9.17.
Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) last posted its quarterly earnings results on Tuesday, May 13th. The biotechnology company reported ($0.13) earnings per share for the quarter, topping analysts' consensus estimates of ($0.16) by $0.03. During the same quarter in the previous year, the company posted ($0.13) EPS. Analysts forecast that Anavex Life Sciences Corp. will post -0.69 EPS for the current year.
Hedge Funds Weigh In On Anavex Life Sciences
Large investors have recently bought and sold shares of the stock. Wellington Management Group LLP acquired a new stake in shares of Anavex Life Sciences in the fourth quarter worth $1,704,000. Cambridge Investment Research Advisors Inc. increased its position in shares of Anavex Life Sciences by 197.7% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 248,139 shares of the biotechnology company's stock worth $2,129,000 after acquiring an additional 164,792 shares in the last quarter. Heartland Advisors Inc. acquired a new stake in shares of Anavex Life Sciences in the fourth quarter worth $1,674,000. PVG Asset Management Corp increased its position in shares of Anavex Life Sciences by 503.5% in the fourth quarter. PVG Asset Management Corp now owns 78,490 shares of the biotechnology company's stock worth $843,000 after acquiring an additional 65,485 shares in the last quarter. Finally, Virtu Financial LLC acquired a new stake in shares of Anavex Life Sciences in the fourth quarter worth $967,000. Hedge funds and other institutional investors own 31.55% of the company's stock.
Anavex Life Sciences Company Profile
(
Get Free Report)
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.
See Also
Before you consider Anavex Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Anavex Life Sciences wasn't on the list.
While Anavex Life Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
